Abstract
Among the recently well appreciated non-motor symptoms in Parkinson’s disease (PD), depression plays a prominent role due to its frequency and impact on quality of life. However, depression may be confounded by motor symptoms, especially akinesia and other non-motor symptoms such as apathy, anxiety and dementia. Data on specific diagnostic tools or treatment for depressive symptoms in PD patients are still sparse. Here we summarize an expert opinion based on available data and clinical experience.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barone P, Poewe W, Albrecht S, Debieuvre C, Massey D, Rascol O, Tolosa E, Weintraub D (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:573–580
Brown RG, MacCarthy B, Gotham AM, Der GJ, Marsden CD (1988) Depression and disability in Parkinson’s disease: a follow-up of 132 cases. Psychol Med 18:49–55
Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, Destee A, Bordet R, Defebvre L (2008) Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord 23:850–857
Kummer A, Cardoso F, Teixeira AL (2009) Suicidal ideation in Parkinson’s disease. CNS Spectr 14:431–436
Lemke MR (2008) Depressive symptoms in Parkinson’s disease. Eur J Neurol 15((Suppl 1)):21–25
Marsh L, McDonald WM, Cummings J, Ravina B (2006) Provisional diagnostic criteria for depression in Parkinson’s disease: report of an NINDS/NIMH Work Group. Mov Disord 21:148–158
Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A (2009) A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 72:886–892
Meyer PM, Strecker K, Kendziorra K, Becker G, Hesse S, Woelpl D, Hensel A, Patt M, Sorger D, Wegner F et al (2009) Reduced alpha4beta2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 66:866–877
Remy P, Doder M, Lees A, Turjanski N, Brooks D (2005) Depression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128:1314–1322
Starkstein SE, Merello M, Jorge R, Brockman S, Bruce D, Petracca G, Robinson RG (2008) A validation study of depressive syndromes in Parkinson’s disease. Mov Disord 23:538–546
Storch A, Ebersbach G, Fuchs G, Jost WH, Odin P, Reifschneider G, Bauer M (2008) Depression in Parkinson’s disease. Part 1: epidemiology, signs and symptoms, pathophysiology and diagnosis. Fortschr Neurol Psychiatr 76:715–724
Strecker K, Wegner F, Hesse S, Becker GA, Patt M, Meyer PM, Lobsien D, Schwarz J, Sabri O (2011) Preserved serotonin transporter binding in de novo Parkinson’s disease: negative correlation with the dopamine transporter. J Neurol 258:19–26
Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Cherif AA (2002) Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 59:408–413
Conflict of interest
All authors received honoraria from various pharmaceutical companies such as Boehringer Ingelheim, GSK, Teva, Lundbeck, Novartis, Desitin, UCB, Orion Pharma, Solvay/Abbott, Schering, Bayer, Lilly Cephalon, and Merz.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of a supplement sponsored by GlaxoSmithKline.
Rights and permissions
About this article
Cite this article
Schwarz, J., Odin, P., Buhmann, C. et al. Depression in Parkinson’s disease. J Neurol 258 (Suppl 2), 336–338 (2011). https://doi.org/10.1007/s00415-011-6048-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-011-6048-3